Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a, Open-label, Multicenter, Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB548 in Participants With Advanced Solid Malignancies With a KRAS G12D Mutation

NCT07207707 is registered in ClinicalTrials.gov with Kumquat Biosciences Inc. as lead sponsor.

NCT NCT07207707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07207707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a, Open-label, Multicenter, Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB548 in Participants With Advanced Solid Malignancies With a KRAS G12D Mutation
Lead sponsor
Kumquat Biosciences Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
September 16, 2025
Completion date
March 31, 2027
Enrollment
78 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor malignancies